The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma
Anticancer Research · 2024
DOI: 10.21873/anticanres.17226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Dirk Rades und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de. Hauptthemen laut MEDLINE: Glioblastoma, Neoplasm Recurrence, Local, Brain Neoplasms.
Abstract (Originalsprache)
BACKGROUND/AIM: The prognostic value of scoring instruments was described for newly diagnosed glioblastoma. This study investigated five instruments in patients with recurrent tumors. PATIENTS AND METHODS: Original Glasgow Prognostic Score (oGPS), modified GPS (mGPS), high-sensitivity mGPS (HS-mGPS), high-sensitivity oGPS (HS-oGPS), LabBM score, and 10 other factors were analyzed for progression-free survival (PFS) and overall survival (OS) in 51 patients. RESULTS: On univariate analyses, oGPS 0-1, mGPS 0-1, and LabBM score 0-1.0 were significantly associated with improved OS and showed trends for improved PFS. On multivariate analysis, a trend was found for associations between LabBM score 0-1.0 and better OS. In addition, maximal cumulative diameter ≤40 mm and systemic therapy were independently associated with better PFS and OS, resection with PFS, and in-field recurrence with OS. CONCLUSION: Lower oGPS, mGPS, and LabBM scores were significantly associated with improved OS on univariate analyses. These instruments may be helpful when designing personalized treatment regimens for patients with recurrent glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de.
- Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
- Department of Radioneurosurgery, Romodanov Neurosurgery Institute, Kyiv, Ukraine.
- Department of Neurosurgery, University of Lübeck, Lübeck, Germany.
- Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, U.S.A.
Zitieren
APA
Rades, D., Zemskova, O., Leppert, J., & Yu, N. Y. (2024). The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma. Anticancer Research. https://doi.org/10.21873/anticanres.17226
Vancouver
Rades D, Zemskova O, Leppert J, Yu NY. The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma. Anticancer Research. 2024. doi:10.21873/anticanres.17226
BibTeX
@article{Rades2024,
author = {Rades, Dirk and Zemskova, Oksana and Leppert, Jan and Yu, Nathan Y},
title = {The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17226}
}
EUVIMED